Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.